Hepatitis B reactivation after lamivudine.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000254:growth & development; D006801:Humans; D019259:Lamivudine; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D014775:Virus Activation; D016047:Zalcitabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000998:Antiviral Agents; D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; D019259:Lamivudine; D016047:Zalcitabine; D000410:Alanine Transaminase; D011241:Prednisone